CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

Please provide your email address to receive an email when new articles are posted on . The FDA based brensocatib’s approval on phase 3 ASPEN and phase 2 WILLOW trial results. This marks the first ...

Please provide your email address to receive an email when new articles are posted on . Brensocatib given as 10 mg or 25 mg performed better than placebo for three outcomes related to pulmonary ...

The case suggests lung transplantation can be a feasible option for patients with lung involvement. A new case report is adding complexity to scientists’ understanding of a rare lysosomal storage ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...

Credit: Insmed. Brensocatib is an oral, reversible inhibitor of dipeptidyl peptidase 1. Treatment with brensocatib 10mg and 25mg significantly reduced the annual rate of pulmonary exacerbations in ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...

Brensocatib has demonstrated efficacy in reducing neutrophil serine protease activity and symptom burden in non-cystic fibrosis bronchiectasis. GLP-1 inhibitors show potential in managing obstructive ...

The FDA has approved brensocatib tablets in 10-mg and 25-mg doses as once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children aged 12 years or older, according to a ...

Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...